Introduction
Acute graft vs host disease (aGVHD), a clinicopathologic syndrome driven by alloreactive donor T cells directed against major and minor histocompatibility antigens of the recipient, is a major obstacle to successful allogeneic hematopoietic cell transplantation. aGVHD develops in greater than 50% of recipients of allogeneic hematopoietic cell transplantation despite prophylaxis, and only 30-40% of those with aGVHD achieve complete response (CR) with standard glucocorticoid front-line therapy. [1] [2] [3] [4] [5] [6] [7] Steroid-refractory aGVHD, defined as aGVHD grade progression within 3 days of initiation of steroids or failure to show improvement by 5 days, is associated with only a 5-30% survival. 5, [8] [9] [10] [11] A number of therapeutic agents directed at the immune cascade underlying aGVHD have shown modest activity in steroid-refractory aGVHD. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Mycophenolate mofetil (MMF), whose metabolite mycophenolic acid inhibits the de novo synthesis of purines in lymphocytes, has probable efficacy in the treatment of aGVHD, based on three small case series that cumulatively reported 17 cases in which MMF was used for initial therapy for aGVHD, and 16 cases with glucocorticoidrefractory aGVHD. [31] [32] [33] Here, we report outcomes in a series of 27 recipients of allogeneic hematopoietic cell transplantation treated with MMF as salvage therapy for steroid-refractory aGVHD.
Methods
A series of 27 patients with steroid-refractory aGVHD, as defined by grade progression within 3 days or failure to achieve grade improvement over 5 days after initiation of glucocorticoid therapy, was retrospectively selected among 509 allogeneic transplant patients treated at the Moffitt Cancer Center between 1998 and 2007. This study was approved as a retrospective review of non-consecutive patients by the University of South Florida Institutional Review Board. Starting doses of systemic prednisone or methylprednisolone ranged from 1-2 mg/kg. No other salvage therapies were used before MMF in these 27 cases. Baseline characteristics are shown in Table 1 . Data on aGVHD were collected on day of onset, and thereafter weekly; organ-specific grade and overall grade were assigned according to the Glucksberg's modified consensus criteria. 34 All cases of aGVHD were biopsy confirmed in at least one organ. Both classic aGVHD occurring within 100 days after HCT and persistent or late aGVHD occurring after 100 days, in the absence of features consistent with cGVHD, were included in this sample. Data collection also included initial dose of glucocorticoids, duration of steroid exposure and overall duration of immunosuppression, incidence and severity of chronic GVHD, 35 CMV reactivation, primary disease relapse, and death. Additional agents used after MMF for ongoing refractory aGVHD were recorded.
Response rates for aGVHD resolution were calculated, with CR to MMF defined as complete resolution of aGVHD after initiation of MMF alone sustained for at least 1 month; partial response was defined as overall grade improvement of one or more. Those that had persistent aGVHD after initiation of MMF requiring additional salvage agents were assessed as non-responders to MMF. Any recurrent episodes of aGVHD until date of death or last follow-up were noted. Univariate logistic regression analysis was performed to examine the relationship of baseline characteristics with CR of aGVHD with MMF. Cumulative incidence of malignancy relapse, chronic GVHD, and CMV reactivation were calculated. The Kaplan-Meier method was used to estimate not only overall survival (OS) and relapse-free survival (RFS), but also several time events including time to less than 20 mg prednisone, time to liberation from prednisone, and time to complete liberation from immune suppression. Survival end points were calculated with the MMF start date as the baseline. RFS was defined by the absence of relapse or death. OS and RFS were examined according to baseline characteristics with the Cox proportional hazard model. Adverse effects from MMF therapy are described.
Results
A total of 27 patients with steroid-refractory aGVHD treated with MMF as salvage therapy were identified. Baseline characteristics are summarized in Table 1 . MMF was used as a second-line therapy at a dose of 1-1.5 g b.i.d., orally or intravenously, after failure of front-line glucocorticoids, with a median time from transplant to initiation of MMF of 40 (range 8-200) days, and median time from initiation of glucocorticoids to initiation of MMF of 12 (range 1-59) days. The original prophylactic tacrolimus or cyclosporine was continued as well. No serum MMF levels were measured. MMF was discontinued in five patients: neutropenia (two), persistent GVHD (one), relapse of the primary disease (one), and complete GVHD resolution (one).
The aGVHD grade was examined at baseline just before MMF initiation, then weekly thereafter (see Figure 1 ). We observed a progressive increase in the proportion of patients with overall grade 0 scores after MMF therapy, (95% CI: 0.7-72.6, P ¼ 0.09). The CR rates with MMF according to organ involvement were the following: skin 3/ 13 or 23%; GI 6/22 or 27%; and liver 1/6 or 17%. On univariate analysis, organ involvement was not significantly associated with CR with MMF. All other baseline characteristics were not significantly related to achievement of CR with MMF alone. At the discretion of the treating physician, patients were treated with additional agents for persistent aGVHD after the initiation of MMF: these agents included infliximab (n ¼ 10), rapamycin (n ¼ 6), ATG (n ¼ 5), pentostatin (n ¼ 3), extracorporeal photopheresis (n ¼ 3), thalidomide (n ¼ 2), denileukin diftitox (n ¼ 2), PUVA (n ¼ 1), and mesenchymal stem cells (n ¼ 1). Allowing for both MMF and additional salvage agents, an additional nine patients experienced CR, so that a total of 16/27 (59%) patients achieved aGVHD resolution by time of death or last follow-up. Agents or therapies successful in inducing CR in these eight patients included infliximab (n ¼ 1), rapamycin (n ¼ 4), rapamycin and infliximab (n ¼ 1), thalidomide (n ¼ 1), and PUVA (n ¼ 1).
On complete follow-up, three experienced recurrent aGVHD; one had recurrent aGVHD at 10 weeks after original CR, and responded to sirolimus as a salvage therapy; one had an overlap syndrome at 10 months after original CR, and was successfully salvaged with infliximab; finally, one had recurrent aGVHD at 11 months after original CR in the setting of withdrawal of immunosuppression and donor-lymphocyte infusion for relapsed myelofibrosis.
With a median follow-up of 8 (range 2-45) months, the median OS was 8.4 months (95% CI: 1.5-not reached), with a Kaplan-Meier OS estimate at 3 years of 40% with no events occurring between 13-42 months (see Figure 2) . OS was 57.1% in those who achieved CR with only MMF as salvage therapy, and rather 34.2% in all others. Hazard ratio (HR) for death in the group with CR to MMF alone compared with all others was 0.4 (95% CI: 0.1-1.6; P ¼ 0.2). However, achievement of CR of aGVHD in total, allowing for both those with CR to MMF alone and those who achieved CR after MMF and additional salvage agents, was a significant predictor of OS, with HR 0.1 (95% CI: 0.04-0.4; P ¼ 0.0004). Additionally, overall aGVHD grade at time of salvage was significantly associated with OS, with OS for grade I/II of 59% and for grade III/IV 19% (log rank P ¼ 0.001). HR for death in grade I/II vs III/IV was 0.18 (95% CI: 0.06-0.57, P ¼ 0.003). None of the seven with grade IV aGVHD at salvage survived. No other baseline characteristics were significantly related to OS.
The cumulative incidence of malignancy relapse was 22%. RFS estimate at 3 years was 34%. Remission status at time of transplant was significantly associated with RFS; HR for those not in remission was 5.1 (1.1-22.8), P ¼ 0.03. Of the 11 patients who died of non-relapse causes, the cause of death included hepatic VOD (n ¼ 1), respiratory failure or pneumonia (n ¼ 3), sepsis (n ¼ 2), and refractory aGHVD (n ¼ 5).
In total in this series, five patients expired directly from infectious complications: Enterococcus faecalis urosepsis in the setting of severe neutropenia (one), E. aerogenes urosepsis (one), Staphylococcus aureus septicemia (one), Candida glabrata and Fusarium sp fungemia (one), Cytomegalovirus pneumonitis (one). Reactivation of CMV was monitored by weekly serum CMV PCR; on reactivation, preemptive therapy with valgancyclovir or gancyclovir was initiated. In CMV seropositive recipients, 11/13 (85%) experienced CMV reactivation, whereas in CMV seronegative recipient/seropositive donor pairs, 2/4 (50%) had CMV reactivation after transplantation. In matched seronegative pairs, none experienced CMV reactivation.
Steroid-refractory aGVHD was associated with a substantial burden of immunosuppression, and a prolonged duration of steroid exposure in this series. Of 19 patients who did not relapse, 6 (32%) developed cGVHD whereas 13 (68%) did not. The median time to reach a dose equivalent of less than 20 mg of prednisone was 16.5 (95% CI: 6.0-22.1) months, and median time to liberation from glucocorticoids was 21.4 (95% CI: 14.5-not reached) months. MMF was discontinued in one patient after a total duration of MMF therapy of 27 months after sustained resolution of GVHD. By the time of last follow-up, no patients had reached liberation from all immunosuppressants.
Discussion
The series reported here most clearly shows efficacy of MMF as a salvage therapy in steroid-refractory aGVHD, and suggests that MMF is a viable option in the management of steroid-refractory aGVHD. The true contribution of an agent as salvage therapy in steroid-refractory aGVHD is difficult to discern, as randomized trials are difficult to conduct, and often several agents are used in succession in the clinical setting. This is further confounded by variable practice patterns in the duration of time allotted to each line of salvage therapy to assess its maximal response before initiating additional agents. The most accurate estimate of the efficacy of MMF in resolution of steroid-refractory aGVHD in this series is when MMF as a single agent induced CR, namely a CR rate of 26%; importantly, MMF shows limited activity in grade III/IV steroid-refractory aGVHD in this series. The efficacy of MMF as reported in this series is at least comparable to that reported for other agents used in this setting. Additionally, OS reported here is within the range of reported survival among alternative agents used for steroidrefractory aGVHD. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] MMF was overall well tolerated, with the majority of those treated here remaining on therapy without dose reduction or significant adverse events directly referable to this agent; only two patients required discontinuation of MMF on account of myelosuppression. However, though a direct causal role cannot be assigned to MMF, the overall burden of immunosuppression and related infectious complications certainly contributed to the morbidity and mortality seen in this series. Of those patients who expired of causes directly related to infectious complications, only two patients suffered from T-cell-dependent etiologic agents, such as Cytomegalovirus and C. glabrata. Obviously, these patients were also treated with other agents for ongoing refractory aGVHD. Careful monitoring for opportunistic infections in the setting of immunosuppressive treatment for refractory aGVHD is of vital importance.
MMF has been examined as salvage therapy in this setting in a number of small series to date. [31] [32] [33] [36] [37] [38] Direct comparisons to other series examining MMF in refractory GVHD are difficult for several reasons. Basara et al. reported an overall grade improvement in 65% of patients, where MMF was used as first-line therapy in addition to CSA and prednisolone on development of aGVHD or cGHVD. Krejci et al. reported an overall response rate of 62% in subjects with either acute or chronic GVHD. The front-line treatment included CSA, 2 mg/kg glucocorticoids; MMF was added with lack of response over 7 days. In Baudard et al., both aGVHD and cGVHD were examined. In those with aGVHD, 4/6 patients had grade improvement; however, those treated with MMF included steroid-resistant, and steroid-or cyclosporine-intolerant aGVHD. Efficacy of MMF in GVHD therapy has also been proposed by the early report of a trial of primary aGVHD therapy in which MMF was used in adjunct to prednisone. 39 The use of MMF in primary therapy of aGVHD implies unnecessary risk and drug cost for the 30% or so of patients who would achieve CR to prednisone alone.
Steroid-refractory aGVHD is a significant contributor to transplant-related morbidity and mortality. Although a number of agents directed at the immune cascade involved have shown activity with moderate response rates, longterm survival remains elusive for most, with competing threats from refractory aGVHD, cGVHD, opportunistic infections, multi-organ dysfunction and failure, and primary disease relapse. MMF seems relatively safe and has efficacy in a quarter of the patients with steroid-refractory aGVHD. There are no randomized controlled data to support the use of one agent over another in steroidrefractory aGVHD. Additionally, there is insufficient data to guide the rational use of additional agents in succession with incomplete response to MMF as a salvage therapy; further work is needed to better inform this approach. Finally, the poor outcomes realized with advanced grade, steroid-refractory aGVHD further show the need for more effective prophylaxis as well as primary therapy of aGVHD, as exemplified by BMT CTN trial 0302.
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